Urothelial cancer -Blaaskanker
Conditions
Interventions
- Peripheral blood samples
- Urine samples
- Tumor biopties
Sponsors
The Netherlands Cancer Institute- Antoni van Leeuwenhoek
Eligibility
Inclusion criteria
Inclusion criteria: - Indication for systemic treatment with anti-cancer agents in patients with urothelial cancer. - WHO performance status 0-2 - age > 18yr - Written informed consent
Exclusion criteria
Exclusion criteria: - Coleection of tissue from a metastatic or primary lesion is not possible. - Pure non-urothelial carcinoma (SCC/Adenocarcinoma) of the bladder or urinary tract
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To explore the longitudinal kinetics of tumor mutations in the urine and plasma of bladder cancer patients receicing systemic therapy fo locally advanced cancer or metastatic disease. | — |
Secondary
| Measure | Time frame |
|---|---|
| - To determine the detectability rate and range in levels ctDNA in plasma before start of treatment - To explore the correlation of levels of ctDNA in plasma with tumor burden - To explore the correlation between radiological response and urine ctDNA and plasma ctDNA kinetics during and following treatment - To explore the prognostic value of urine ctDNA and plasma ctDNA for treatment outcome (progression free survival) of neoadjuvant chemotherapy for bladder cancer - To explore the range and frequency of mutations found in ctDNA, urine ctDNA and tumor samples in bladder cancer. - Build a biobank of longitudinally collected bladder cancer samples for translational research. | — |
Contacts
Public ContactM.S. Heijden, van der
Nederlands Kanker Instituut/Dutch Cancer Institute
Outcome results
None listed